Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients. To increase molecular response ratio we decided to increase imatinib dose to limited resistance to this drug and to add zoledronate for it anti tumoral activity to increase anti leukemic effect. We plan to accrue 37 patients in 5 centers. We will analyse molecular expression of BCR-ABL transcript after 6 months of treatment, safety, duration of response, VEGF expression and LTgd production.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
19
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France
Centre Hospitalier de Versailles
Le Chesnay, France
Hôpital Edouard Herriot
Lyon, France
Hôpital Archet
Nice, France
Hôpital Saint Louis
Paris, France
Centre Hospitalier Universitaire de Poitiers
Poitiers, France
Percentage of Participants With Molecular Response
A patient is considered to be in molecular response if at least one of the following conditions is observed : \- a complete molecular response at 6 months defined by PCR negativation tested on twice OR \- reduction of BCR-ABL transcript level \> 2 Log from the start of from initiation of treatment
Time frame: 6 months
Percentage of Participants With a Reduction of BCR-ABL Transcript Level > 4.5 Log From the Start of From Initiation of Treatment
reduction of BCR-ABL transcript level \> 4.5 Log from the start of from initiation of treatment
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.